

WHAT IS CLAIMED IS:

1. A liquid formulation of a therapeutic agent comprising:
  - 5 rapamycin in a pharmaceutically effective dosage; and one or more pharmaceutically acceptable solubility enhancers.
  2. The liquid formulation according to claim 1, further comprising one or more pharmaceutically acceptable stabilizers.
    - 10 3. The liquid formulation according to claim 2, wherein the concentration of rapamycin in solution is in the range from about 1 mg/ml to about 15 mg/ml.
    - 15 4. The liquid formulation according to claim 3, wherein the rapamycin comprises sirolimus.
    5. The liquid formulation according to claim 3, wherein the rapamycin comprises CCI-779.
      - 20 6. The liquid formulation according to claim 2, wherein the one or more pharmaceutically acceptable stabilizer and solubility enhancers comprises polyethylene glycol.
      - 25 7. The liquid formulation according to claim 2, wherein the one or more pharmaceutically acceptable stabilizer and solubility enhancers comprises Vitamin E TPGS.
      - 30 8. The liquid formulation according to claim 1, further comprising water.
    9. A method for the treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site.

10. The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.